Label Changes for:
Nucynta (tapentadol) Immediate-release Oral Tablets
Changes have been made to the ADVERSE REACTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – November 2010
- Nervous system disorders: headache
- Psychiatric disorders: hallucination